Frontlight ResearchEarly access
Taking peoplePhase 4
Aspirin for the Prevention of Preeclampsia and Pregnancy outcomes in nulliparous women after Assisted Reproductive Technology.
Key facts
- Who runs it
- Centre Hospitalier Universitaire De Toulouse
- Where
- France22 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 1,164 people, planned
- Started
- 2 Aug 2023
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional
- Record updated
- 20 May 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Nulliparous women aged 18 years or more
- Pregnancy following ART, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), oocyte donation or intrauterine insemination with sperm donor
- Singleton pregnancy
- Evolutive pregnancy between 9 and 15 (+6 days) weeks of gestation
- Women affiliated to a French Social Security Insurance or equivalent social protection
- Written informed consent
Who cannot take part
- Regular treatment with aspirin (including antiphospholipid syndrome)
- Patient included in another drug study or another interventional study which could interfere with the results of the study
- Aspirin contraindications (allergy, von Willebrand disease, peptic ulceration, hemophilia)
- Major fetal abnormality
- Women protected by law
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Evaluate the effect of aspirin 150mg daily initiated between 9 and 15(+6 days) weeks of gestation versus placebo in the prevention of preterm (<37 weeks of gestation) preeclampsia in nulliparous pregnant women after assisted reproductive technology.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Aspirin for the Prevention of Preeclampsia and Pregnancy outcomes in nulliparous women after Assisted Reproductive Technology. APPART trial
- Criteria questions
- Built from 2022-500933-10-00, who can take part
- Record updated
- 20 May 2026